NAVB logo

NAVB Cash From Financing

Annual CFF

$7.14 M
-$4.97 M-41.01%

December 31, 2022

Summary

Performance

1-Year Change

-41.01%

3-Year Change

+16.02%

5-Year Change

+111.71%

15-Year Change

+111.71%

NAVB Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

53.18%
NAVB annual cash flow from financing activities is higher than 53.18% of companies in Healthcare sector

High & Low

All-time High

$60.72 M
NAVB annual cash flow from financing activities is currently -88.24% below its historical high of $60.72 million

3-Year Low

$7.14 M
NAVB annual cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
NAVB previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

Feb 12, 2025
NAVB next annual earnings announcement is scheduled for Feb 12, 2025

OtherNAVBcash flowmetrics:

Annual CFI

-$390.30 K
NAVB annual cash flow from investing activities is -$390.30 thousand

Annual CFO

-$8.99 M
NAVB annual cash flow from operations is -$8.99 million

Annual FCF

-$9.38 M
NAVB annual free cash flow is -$9.38 million

Annual CAPEX

$390.30 K
NAVB annual capital expenditures is $390.30 thousand

Quarterly CFF

-$188.60 K
-$1.67 M-112.70%

September 30, 2023

Summary

Performance

3-Month Change

-112.7%

1-Year Change

-112.7%

3-Year Change

-112.7%

5-Year Change

-112.7%

NAVB Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

27.76%
NAVB quarterly cash flow from financing activities is higher than 27.76% of companies in Healthcare sector

High & Low

All-time High

$32.00 M
NAVB quarterly cash flow from financing activities is currently -100.59% below its historical high of $32.00 million

3-Year Low

-$339.50 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
NAVB previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

Feb 12, 2025
NAVB next earnings announcement is scheduled for Feb 12, 2025

OtherNAVBcash flowmetrics:

Quarterly CFI

-$524.70 K
NAVB quarterly cash flow from investing activities is -$524.70 thousand

Quarterly CFO

-$10.25 M
NAVB quarterly cash flow from operations is -$10.25 million

Quarterly FCF

-$10.27 M
NAVB quarterly free cash flow is -$10.27 million

Quarterly CAPEX

-
NAVB quarterly capital expenditures value is unknown

TTM CFF

$995.70 K
-$6.40 M-86.53%

September 30, 2023

Summary

Performance

3-Month Change

-86.53%

1-Year Change

-86.53%

3-Year Change

-86.53%

5-Year Change

-86.53%

NAVB TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

33.01%
NAVB TTM cash flow from financing activities is higher than 33.01% of companies in Healthcare sector

High & Low

All-time High

$66.04 M
NAVB TTM cash flow from financing activities is currently -98.49% below its historical high of $66.04 million

3-Year Low

$995.70 K
NAVB TTM cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
NAVB previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

Feb 12, 2025
NAVB next earnings announcement is scheduled for Feb 12, 2025

OtherNAVBcash flowmetrics:

TTM CFI

-$701.10 K
NAVB TTM cash flow from investing activities is -$701.10 thousand

TTM CFO

-$9.71 M
NAVB TTM cash flow from operations is -$9.71 million

TTM FCF

-$9.91 M
NAVB TTM free cash flow is -$9.91 million

TTM CAPEX

-
NAVB TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

NAVB Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-41.0%-112.7%-86.5%
3 y3 years+16.0%-112.7%-86.5%
5 y5 years+111.7%-112.7%-86.5%

NAVB Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-41.0%at low-103.0%+44.5%-91.8%at low
5 y5-year-41.0%+16.0%-102.4%+44.5%-94.3%at low
alltimeall time-88.2%+111.7%-100.6%+99.7%-98.5%+101.4%

Navidea Biopharmaceuticals Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2023
-
-$188.60 K(-112.7%)
$995.70 K(-86.5%)
Jun 2023
-
$1.48 M(-840.4%)
$7.39 M(+1.6%)
Mar 2023
-
-$200.50 K(+100.9%)
$7.28 M(+1.9%)
Dec 2022
$7.14 M(-41.0%)
-$99.80 K(-101.6%)
$7.14 M(+0.4%)
Sep 2022
-
$6.21 M(+352.8%)
$7.11 M(+128.6%)
Jun 2022
-
$1.37 M(-503.9%)
$3.11 M(-18.1%)
Mar 2022
-
-$339.50 K(+166.3%)
$3.80 M(-68.6%)
Dec 2021
$12.11 M(+18.6%)
-$127.50 K(-105.8%)
$12.11 M(-12.4%)
Sep 2021
-
$2.21 M(+7.1%)
$13.82 M(-16.5%)
Jun 2021
-
$2.06 M(-74.1%)
$16.56 M(-6.0%)
Mar 2021
-
$7.97 M(+402.0%)
$17.61 M(+72.4%)
Dec 2020
$10.21 M(+65.9%)
$1.59 M(-67.9%)
$10.21 M(+6.1%)
Sep 2020
-
$4.94 M(+59.0%)
$9.62 M(+109.3%)
Jun 2020
-
$3.11 M(+445.5%)
$4.60 M(-32.3%)
Mar 2020
-
$570.00 K(-42.8%)
$6.79 M(+10.3%)
Dec 2019
$6.16 M(-235.3%)
$997.00 K(-1346.3%)
$6.16 M(+21.1%)
Sep 2019
-
-$80.00 K(-101.5%)
$5.08 M(-37.1%)
Jun 2019
-
$5.31 M(-8018.8%)
$8.08 M(-279.7%)
Mar 2019
-
-$67.00 K(-13.4%)
-$4.50 M(-1.1%)
Dec 2018
-$4.55 M(-92.5%)
-$77.40 K(-102.7%)
-$4.55 M(+0.4%)
Sep 2018
-
$2.92 M(-140.1%)
-$4.53 M(-39.5%)
Jun 2018
-
-$7.27 M(+6057.9%)
-$7.50 M(+2012.6%)
Mar 2018
-
-$118.10 K(+96.5%)
-$354.80 K(-99.4%)
Dec 2017
-$61.00 M(+567.0%)
-$60.10 K(+34.5%)
-$61.00 M(-2.4%)
Sep 2017
-
-$44.70 K(-66.1%)
-$62.46 M(-4.5%)
Jun 2017
-
-$131.90 K(-99.8%)
-$65.42 M(-6.4%)
Mar 2017
-
-$60.76 M(+3874.3%)
-$69.90 M(+664.4%)
Dec 2016
-$9.14 M(-144.0%)
-$1.53 M(-49.1%)
-$9.14 M(+20.1%)
Sep 2016
-
-$3.00 M(-35.0%)
-$7.62 M(+54.0%)
Jun 2016
-
-$4.61 M(>+9900.0%)
-$4.94 M(-128.6%)
Mar 2016
-
-$700.00(0.0%)
$17.29 M(-16.8%)
Dec 2015
$20.79 M(+551.4%)
-$700.00(-99.8%)
$20.79 M(+0.3%)
Sep 2015
-
-$328.90 K(-101.9%)
$20.74 M(-1.6%)
Jun 2015
-
$17.62 M(+403.5%)
$21.06 M(+509.0%)
Mar 2015
-
$3.50 M(-6417.1%)
$3.46 M(+8.4%)
Dec 2014
$3.19 M(-94.7%)
-$55.40 K(+9133.3%)
$3.19 M(-0.6%)
Sep 2014
-
-$600.00(-103.9%)
$3.21 M(-90.0%)
Jun 2014
-
$15.20 K(-99.5%)
$32.01 M(-42.3%)
Mar 2014
-
$3.23 M(-8860.2%)
$55.48 M(-8.6%)
Dec 2013
$60.72 M(+1097.8%)
-$36.90 K(-100.1%)
$60.72 M(-8.0%)
Sep 2013
-
$28.80 M(+22.7%)
$66.04 M(+79.4%)
Jun 2013
-
$23.48 M(+176.9%)
$36.80 M(+171.5%)
Mar 2013
-
$8.48 M(+60.8%)
$13.56 M(+167.4%)
Dec 2012
$5.07 M(-54.2%)
$5.27 M(-1319.8%)
$5.07 M(-19.8%)
Sep 2012
-
-$432.40 K(-283.8%)
$6.32 M(-15.8%)
Jun 2012
-
$235.30 K(-3279.7%)
$7.51 M(+26.6%)
Mar 2012
-
-$7400.00(-100.1%)
$5.93 M(-46.4%)
Dec 2011
$11.08 M(+74.4%)
$6.53 M(+764.1%)
$11.08 M(+10.9%)
Sep 2011
-
$755.40 K(-156.3%)
$9.99 M(+9.1%)
Jun 2011
-
-$1.34 M(-126.1%)
$9.15 M(-12.7%)
Mar 2011
-
$5.13 M(-5.6%)
$10.49 M(+65.2%)
Dec 2010
$6.35 M(+96.6%)
$5.44 M(-6974.7%)
$6.35 M(+701.8%)
Sep 2010
-
-$79.10 K(+1421.2%)
$791.90 K(-81.3%)
Jun 2010
-
-$5200.00(-100.5%)
$4.25 M(-0.5%)
Mar 2010
-
$995.60 K(-933.8%)
$4.27 M(+32.1%)
Dec 2009
$3.23 M(-43.1%)
-$119.40 K(-103.5%)
$3.23 M(-47.3%)
Sep 2009
-
$3.38 M(>+9900.0%)
$6.13 M(+115.1%)
Jun 2009
-
$15.70 K(-137.6%)
$2.85 M(-49.0%)
Mar 2009
-
-$41.80 K(-101.5%)
$5.59 M(-1.6%)
Dec 2008
$5.68 M
$2.78 M(+2843.5%)
$5.68 M(+74.3%)
Sep 2008
-
$94.50 K(-96.6%)
$3.26 M(-6.1%)
DateAnnualQuarterlyTTM
Jun 2008
-
$2.75 M(+5845.4%)
$3.47 M(+306.0%)
Mar 2008
-
$46.30 K(-87.3%)
$854.70 K(+143.7%)
Dec 2007
$350.80 K(-245.9%)
$363.30 K(+18.2%)
$350.70 K(-3149.6%)
Sep 2007
-
$307.40 K(+123.2%)
-$11.50 K(-97.2%)
Jun 2007
-
$137.70 K(-130.1%)
-$415.50 K(-33.4%)
Mar 2007
-
-$457.70 K(<-9900.0%)
-$623.70 K(+159.4%)
Dec 2006
-$240.40 K(-12.1%)
$1100.00(-101.1%)
-$240.40 K(-21.7%)
Sep 2006
-
-$96.60 K(+37.0%)
-$307.10 K(+0.8%)
Jun 2006
-
-$70.50 K(-5.2%)
-$304.80 K(-3.5%)
Mar 2006
-
-$74.40 K(+13.4%)
-$315.90 K(+15.5%)
Dec 2005
-$273.40 K(-103.0%)
-$65.60 K(-30.4%)
-$273.40 K(-104.0%)
Sep 2005
-
-$94.30 K(+15.6%)
$6.85 M(-1.6%)
Jun 2005
-
-$81.60 K(+155.8%)
$6.97 M(-5.5%)
Mar 2005
-
-$31.90 K(-100.5%)
$7.37 M(-19.8%)
Dec 2004
$9.19 M(+226.8%)
$7.06 M(>+9900.0%)
$9.19 M(+118.0%)
Sep 2004
-
$19.90 K(-93.8%)
$4.22 M(-9.0%)
Jun 2004
-
$320.50 K(-82.1%)
$4.63 M(-1.1%)
Mar 2004
-
$1.79 M(-14.3%)
$4.68 M(+66.6%)
Dec 2003
$2.81 M(-1200.2%)
$2.09 M(+377.6%)
$2.81 M(-314.5%)
Sep 2003
-
$436.90 K(+17.4%)
-$1.31 M(+65.5%)
Jun 2003
-
$372.00 K(-545.5%)
-$792.30 K(+196.6%)
Mar 2003
-
-$83.50 K(-95.9%)
-$267.10 K(+4.5%)
Dec 2002
-$255.60 K(+36.1%)
-$2.04 M(-313.1%)
-$255.60 K(-115.0%)
Sep 2002
-
$955.90 K(+6.5%)
$1.71 M(+133.1%)
Jun 2002
-
$897.20 K(-1346.1%)
$732.00 K(-443.0%)
Mar 2002
-
-$72.00 K(-4.0%)
-$213.40 K(+13.6%)
Dec 2001
-$187.80 K(-94.3%)
-$75.00 K(+312.1%)
-$187.80 K(+44.4%)
Sep 2001
-
-$18.20 K(-62.2%)
-$130.10 K(-63.5%)
Jun 2001
-
-$48.20 K(+3.9%)
-$356.80 K(-15.2%)
Mar 2001
-
-$46.40 K(+168.2%)
-$420.60 K(-87.3%)
Dec 2000
-$3.31 M(-271.1%)
-$17.30 K(-92.9%)
-$3.31 M(+0.5%)
Sep 2000
-
-$244.90 K(+118.7%)
-$3.29 M(+8.0%)
Jun 2000
-
-$112.00 K(-96.2%)
-$3.05 M(+0.4%)
Mar 2000
-
-$2.94 M(+2837.0%)
-$3.04 M(-183.4%)
Dec 1999
$1.93 M(-50.9%)
-
-
Jun 1999
-
-$100.00 K(-103.7%)
$3.64 M(-14.1%)
Mar 1999
-
$2.70 M(+187.0%)
$4.24 M(+7.6%)
Dec 1998
$3.94 M(+221.1%)
$940.80 K(+840.8%)
$3.94 M(+30.2%)
Sep 1998
-
$100.00 K(-80.0%)
$3.03 M(+3.4%)
Jun 1998
-
$500.00 K(-79.2%)
$2.93 M(+3.5%)
Mar 1998
-
$2.40 M(+8691.2%)
$2.83 M(+130.4%)
Dec 1997
$1.23 M(-97.6%)
$27.30 K(>+9900.0%)
$1.23 M(-92.4%)
Sep 1997
-
$0.00(-100.0%)
$16.20 M(-10.0%)
Jun 1997
-
$400.00 K(-50.0%)
$18.00 M(-63.7%)
Mar 1997
-
$800.00 K(-94.7%)
$49.60 M(-2.6%)
Dec 1996
$50.90 M(+104.4%)
$15.00 M(+733.3%)
$50.90 M(+35.7%)
Sep 1996
-
$1.80 M(-94.4%)
$37.50 M(-17.6%)
Jun 1996
-
$32.00 M(+1423.8%)
$45.50 M(+114.6%)
Mar 1996
-
$2.10 M(+31.3%)
$21.20 M(-14.9%)
Dec 1995
$24.90 M(0.0%)
$1.60 M(-83.7%)
$24.90 M(-43.7%)
Sep 1995
-
$9.80 M(+27.3%)
$44.20 M(+29.2%)
Jun 1995
-
$7.70 M(+32.8%)
$34.20 M(+27.6%)
Mar 1995
-
$5.80 M(-72.2%)
$26.80 M(+7.6%)
Dec 1994
$24.90 M(+1975.0%)
$20.90 M(<-9900.0%)
$24.90 M(+378.8%)
Sep 1994
-
-$200.00 K(-166.7%)
$5.20 M(-5.5%)
Jun 1994
-
$300.00 K(-92.3%)
$5.50 M(+5.8%)
Mar 1994
-
$3.90 M(+225.0%)
$5.20 M(+333.3%)
Dec 1993
$1.20 M(-91.6%)
$1.20 M(+1100.0%)
$1.20 M(>+9900.0%)
Sep 1993
-
$100.00 K(>+9900.0%)
$0.00(-100.0%)
Jun 1993
-
$0.00(-100.0%)
-$100.00 K(0.0%)
Mar 1993
-
-$100.00 K
-$100.00 K
Dec 1992
$14.30 M
-
-

FAQ

  • What is Navidea Biopharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for Navidea Biopharmaceuticals?
  • What is Navidea Biopharmaceuticals annual CFF year-on-year change?
  • What is Navidea Biopharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Navidea Biopharmaceuticals?
  • What is Navidea Biopharmaceuticals quarterly CFF year-on-year change?
  • What is Navidea Biopharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Navidea Biopharmaceuticals?
  • What is Navidea Biopharmaceuticals TTM CFF year-on-year change?

What is Navidea Biopharmaceuticals annual cash flow from financing activities?

The current annual CFF of NAVB is $7.14 M

What is the all time high annual CFF for Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals all-time high annual cash flow from financing activities is $60.72 M

What is Navidea Biopharmaceuticals annual CFF year-on-year change?

Over the past year, NAVB annual cash flow from financing activities has changed by -$4.97 M (-41.01%)

What is Navidea Biopharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of NAVB is -$188.60 K

What is the all time high quarterly CFF for Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals all-time high quarterly cash flow from financing activities is $32.00 M

What is Navidea Biopharmaceuticals quarterly CFF year-on-year change?

Over the past year, NAVB quarterly cash flow from financing activities has changed by -$1.67 M (-112.70%)

What is Navidea Biopharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of NAVB is $995.70 K

What is the all time high TTM CFF for Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals all-time high TTM cash flow from financing activities is $66.04 M

What is Navidea Biopharmaceuticals TTM CFF year-on-year change?

Over the past year, NAVB TTM cash flow from financing activities has changed by -$6.40 M (-86.53%)